Xeljanz (tofacitinib)

pCPA File Number: 20877
Negotiation Status:
Concluded with an LOI
Indication(s):
Subacute and chronic inflammatory joint diseases
Sponsor/Manufacturer:
Pfizer Canada ULC
CADTH Project Number:
SR0380-000
pCPA Engagement Letter Issued:
Negotiation Process Concluded: